Paper Details

  1. Home
  2. Paper Details

Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.

Author: AlotaibiAlaa A, FreedmanMark S, RoyReshmi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Fingolimod, a sphingosine 1-phosphate (S1P) receptor (S1PR) modulator, was the first oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). Second-generation S1PR modulators, such as siponimod, ozanimod, ponesimod, ceralifimod, and amiselimod, have shown promise in treating both relapsing-remitting and secondary progressive MS with improved safety profiles. These agents offer more selective targeting, shorter half-lives, and faster reversal of pharmacological effects compared to fingolimod.
Paper Details　
Original Abstract of the Article :
Fingolimod (Gilenya) received regulatory approval from the US FDA in 2010 as the first-in-class sphingosine 1-phosphate (S1P) receptor (S1PR) modulator and was the first oral disease-modifying therapy (DMT) used for the treatment of the relapsing forms of multiple sclerosis (MS). Development of this...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s40263-021-00798-w

データ提供：米国国立医学図書館（NLM）

Sphingosine 1-Phosphate Receptor Modulators: A New Frontier in Multiple Sclerosis Treatment

Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system. The development of effective treatments for MS has been a major focus in medical research. This review article provides an overview of sphingosine 1-phosphate (S1P) receptor modulators, a new class of drugs that have shown promise in the treatment of MS. The authors discuss the mechanism of action of these drugs, their efficacy, safety profile, and potential for future development. The authors highlight the importance of fingolimod (Gilenya), the first-in-class S1P receptor modulator, which revolutionized MS treatment. They also discuss the development of second-generation S1P receptor modulators, such as siponimod (Mayzent) and ozanimod, which offer improved selectivity and safety profiles. This review provides a comprehensive overview of this exciting new class of drugs and their potential to transform MS treatment.

S1P Receptor Modulators: A New Paradigm in MS Treatment

The authors demonstrate the profound impact of S1P receptor modulators on MS treatment. These drugs offer a new paradigm for managing the disease by targeting specific pathways involved in immune cell trafficking. The development of these drugs has significantly improved the treatment landscape for MS, providing patients with more effective and safer treatment options.

Navigating the Future of MS Treatment

This review highlights the ongoing advancements in MS treatment, particularly the development of S1P receptor modulators. These drugs hold great promise for improving the lives of patients with MS. The authors emphasize the importance of continued research to optimize the use of these drugs and develop even more effective and safe treatment options.

Dr. Camel's Conclusion

The development of S1P receptor modulators is a testament to the tireless efforts of researchers to find new and innovative treatments for MS. These drugs have the potential to significantly impact the lives of patients with MS, offering hope for a better future. The future of MS treatment looks bright, with continued advancements in this promising area.

Date :
  1. Date Completed 2022-01-10
  2. Date Revised 2022-01-10
Further Info :

Pubmed ID

33797705

DOI: Digital Object Identifier

10.1007/s40263-021-00798-w

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.